Molecular Internal Medicine

Literature

Linking regulation of nitric oxide to endothelin-1: the Yin and Yang of vascular tone in the atherosclerotic plaque
R.M. Gupta, P. Libby, M. Barton
Atherosclerosis 2019

In memoriam: Paul M. Vanhoutte
M. Barton, C. Cardillo
J Physiol 2019


Endothelin: 30 years from discovery to therapy
M. Barton, M. Yanagisawa
Hypertension 2019;74:

Nox1 downreglators: A new class of therapeutics
M. Barton, M.R. Meyer, E.R. Prossnitz
Steroids 2019

Potential role for Nox1 for endothelin-induced brain capillary vasoconstriction in Alzheimer's disease and dementia
M. Barton, M.R. Meyer, E.R. Prossnitz.
Science eaav9518, 2019


Primum non nocere: Why calcitriol («vitamin» D) hormone therapy is not a magic bullet
M. Barton
Arterioscler Thromb Vasc Biol 39, 117-120, 2019

Post-myocardial infarction (MI) care: medication adherence for secondary prevention after MI in a large real-world population.
Huber CA, Meyer MR, Steffel J, Blozik E, Reich O, Rosemann T
Clin Ther 41, 107-117, 2019

Permissive role for GPER in arterial hypertension
M. Barton, M.R. Meyer
Hypertension 73, e9-e10, 2019

HuR-ry up: How hydrogen sulfide protects against atherosclerosis
M. Barton, M.R. Meyer
Circulation 139, 155-118, 2019


Gender differences in patient and system delay for primary percutaneous coronary intervention: current trends in a Swiss ST-segment elevation myocardial infarction population
M.R. Meyer, A.M. Bernheim, D.J. Kurz, C.J. O'Sullivan, D. Tüller, R. Zbinden, T. Rosemann, F.R. Eberli
Eur Heart J Acute Cardiovasc Care 8, 283-290, 2019

Self-experimentation and serendipity: How cardiac catheterization led the way to coronary balloon angioplasty
M. Barton
BMJ 363:k5006, 2018

GPER is required for age-dependent albuminuria and glomerulosclerosis: evidence for its role in podocyte injury and mesangial Nox1 regulation
M.R. Meyer, C. Daniel, C.D. Woods, G. Sharma, N.C. Fredette, K. Amann, M. Barton, E.R. Prossnitz
Hypertension 72 (suppl), P261, 2018


Endothelial factors in the pathogenesis and treatment of chronic kidney disease
G.P. Rossi, T. M. Secchia, M. Barton. A.H. Danser, P. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito, N. Hasebe, D.J. Webb.
European Society of Hypertension Scientific Newsletter 19 (67), 1-2, 2018

Hypertrophe und dilatative Kardiomyopathie
M.R. Meyer, F.R. Eberli.
Swiss Medical Forum 18, 168–177, 2018

In Memoriam: Sidney George Shaw, DPhil (1948-2017)
M. Barton, H. J. Little, R.D. Vaughn-Jones, S. Daniels, M.R. Dashwood, M.R. Dashwood, J.C. Tsui.
Physiol Res 67 (Suppl. 1), S-27-S35, 2018


Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: role in disease conditions. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertens 36, 462-471, 2018

Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: general mechanisms. A joint consensus statement from the ESH Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension.
G.P. Rossi, T.M. Seccia, M. Barton, A.H. Danser AH, P.W. de Leeuw, N. Dhaun, D. Rizzoni, P. Rossignol, L.M. Ruilope, A.H. van den Meiracker, S. Ito S, N. Hasebe, D.J. Webb.
J Hypertens 36, 451-461, 2018


Role of GPER in estrogen-dependent nitric oxide formation and vasodilation.
N.C. Fredette, M.R. Meyer, E.R Prossnitz
J Steroid Biochem Mol Biol 76, 65-72, 2018

GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases
M.R. Meyer, M. Barton

J Steroid Biochem Mol Biol 176, 82-87, 2018

Twenty years of G protein-coupled estrogen receptor GPER: historical and personal perspectives
M. Barton, E. J. Filardo, S.J. Lolait, P. Thomas, M. Maggiolini, E.R. Prossnitz
J Steroid Biochem Mol Biol 176, 4-15, 2018

Iron substitution in the treatment of chronic heart failure.
C. Gstrein, M.R. Meyer, P. Anabitarte
Swiss Med Weekly 23; w14453, 2017

Paradoxical lack of increase in endothelin-1 levels in obese mice – possible role of endothelin-B receptors
O. Baretella, S.K. Chung, A. Xu, P.M Vanhoutte
Acta Pharmacologica Sinica 38, 1699–1700, 2017


Rapid vasodilation to raloxifene: role of estrogen receptors and off-target effects
M. Barton, E.R. Prossnitz.
Br J Pharmacol 174, 4201-4202, 2017


GPER mediates functional endothelial aging in renal arteries
M.R. Meyer, T. Rosemann, M. Barton, E.R. Prossnitz.
Pharmacology 100, 188-193, 2017


Obligatory role for GPER in cardiovascular aging and disease
M.R. Meyer, N.C. Fredette, C. Daniel, G. Sharma, K. Amann, J.B. Arterburn, M. Barton, E.R. Prossnitz.
Science Signaling 9, ra105, 2016


Estrogen signaling in the adrenal cortex: implications for blood pressure sex differences
B. Carrocia, T.M. Seccia, M. Barton, G.P. Rossi
Hypertension 68, 840-848, 2016

Efficacy and safety of transcatheter closure in adults with large or small atrial septal defects
M.R. Meyer, D.J. Kurz, A.M. Bernheim, O. Kretschmar. F.R. Eberli
Springerplus 5, 1841, 2016


Estrogens and coronary artery disease: new clinical perspectives
M.R. Meyer, M. Barton
Adv Pharmacol 77, 307-360, 2016

Not lost in translation: Emerging clinical importance of the G protein-coupled estrogen receptor GPER
M. Barton
Steroids 111, 37-45, 2016

GPER is required for the age-dependent upregulation of the myocardial endothelin system
M.R. Meyer, N.C. Fredette, G. Sharma, M. Barton, E.R. Prossnitz
Life Sci 159, 61-65, 2016


Accelerated vascular aging as a paradigm for hypertensive vascular disease: prevention and therapy
M. Barton, M. Husmann, M.R. Meyer
Can J Cardiol 32, 680-686, 2016


G protein-coupled estrogen receptor inhibits vascular prostanoid production and activity
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
J Endocrinol 227, 61-69, 2015

Erratum: G Protein-coupled estrogen receptor protects from atherosclerosis
M.R. Meyer, N.C. Fredette, T.A. Howard, C. Hu, C. Ramesh, C. Daniel, K. Ammann, J.B. Arterburn, M. Barton, E.R. Prossnitz
Sci Rep 5, 13510, 2015

Prostanoid-mediated contractions of the carotid artery become Nox2-independent with aging
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
AGE 37, 79, 2015

Nicolaus Copernicus and the rapid vascular responses to aldosterone
M. Barton, M.R. Meyer
Trends Endocrinol Metab 26, 396-398, 2015

Endothelin and the glomerulus in chronic kidney disease
M. Barton, A. Sorokin
Semin Nephrol 35, 156-167, 2015

Emerging roles of GPER in diabetes and atherosclerosis
M. Barton, E.R. Prossnitz
Trends Endocrinol Metab 26, 185-192, 2015

Balloon angioplasty - the legacy of Andreas Grüntzig, M.D. (1939-1985)
M. Barton, J. Grüntzig, M. Husmann, J. Rösch
Front Cardiovasc Med 1, 15, 2014

Aging and endothelin: determinants of disease
M. Barton
Life Sci 118, 97-109, 2014

G Protein-coupled estrogen receptor protects from atherosclerosis
M.R. Meyer, N.C. Fredette, T.A. Howard, C. Hu, C. Ramesh, C. Daniel, K. Ammann, J.B. Arterburn, M. Barton, E.R. Prossnitz
Sci Rep 4, 7564, 2014

In Memoriam: Wolfgang Kiowski, M.D. (1949-2012) - Pioneer in clinical endothelin research
M. Barton, E.L. Schiffrin
Life Sci 118, 91-96, 2014

Advancing and translating knowledge in vascular medicine
M. Husmann, M. Barton
Front Cardiovasc Med 1, 6, 2014

25 Years of endothelin research: the next generation
N. Emoto, N. Vignon-Zellweger, R.A. Lopes, J. Cacioppo, L. Debiens, D. Kamato, T. Leurgans, R. Moorhouse, J. Straube, R. Wurm, S. Heiden, A. Ergul, M. Yanagisawa, M. Barton
Life Sci 118, 77-86, 2014

Endothelin and endothelin antagonists in chronic kidney disease
D.E. Kohan, M. Barton
Kidney Int 86, 896-904, 2014

Endothelin-1 but not angiotensin II contributes to functional aging in murine carotid arteries
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
Life Sci 118, 213-218, 2014

Obesity and heterozygous endothelial overexpression of prepro-endothelin-1 modulate responsiveness of mouse main and segmental renal arteries to vasoconstrictor agents
O. Baretella, S.K. Chung, M. Barton, A. Xu, P.M. Vanhoutte
Life Sci
118, 206-212, 2014

Functional heterogenity of NADPH oxidase-mediated contractions to endothelin with vascular aging
M.R. Meyer, M. Barton, E.R Prossnitz

Life Sci 118, 226-231, 2014

Estrogen biology: New insights on GPER function and clinical opportunities
E.R Prossnitz, M. Barton
Mol Cell Endocrinol 389, 71-83, 2014

Regulation of vascular smooth muscle tone by Adipose-Derived Contracting Factor
M.R. Meyer, N.C. Fredette, M. Barton, E.R. Prossnitz
PLoS ONE 8, e79245, 2013

Endothelin in coronary artery disease and myocardial infarction
T.M. Kolettis, M. Barton, D. Langleben, Y. Matsumura

Cardiol Rev 24, 124-220, 2013

Alike but not the same: anatomic heterogeneity of estrogen receptor-mediated vasodilation
M. Barton, M.R. Meyer, E.R Prossnitz

J Cardiovasc Pharmacol 62, 22-25, 2013

Prevention and endothelial therapy of coronary artery disease
M. Barton
Curr Opin Pharmacol 13, 225-241, 2013

Mechanisms and therapy of atherosclerosis and its clinical complications
M. Barton

Curr Opin Pharmacol 13, 149-153, 2013

Cholesterol and atherosclerosis: Modulation by estrogen
M. Barton

Curr Opin Lipidol 24, 214-220, 2013

Childhood obesity: Preventing today's children from becoming tomorrow's patients
M. Barton

IFAVA Scientific Newsletter 75, 1, 2013

Themed section: Endothelin
A.P. Davenport, M. Barton
Br J Pharmacol 168, 269-272, 2013

Endothelin XII - Editorial
M. Barton, M. Yanagisawa, P.M. Vanhoutte, T. Masaki

Life Sci 91, 449-451, 2012

The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011
M. Barton, A.P. Davenport
Life Sci 91, 462-465, 2012

The First Tomoh Masaki Award (2011)
M. Barton, N. Emoto, T. Miyauchi

Life Sci 91, 466-469, 2012

Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?
D.E. Kohan, J.G. Cleland, L.J. Rubin, D. Theodorescu, M. Barton

Life Sci 91, 528-539, 2012

The future of endothelin research: scientific mentoring and beyond
M. Barton, D.M. Pollock

Life Sci 91, 470-474, 2012

GPER regulates endothelin-dependent vascular tone and intracellular calcium
M.R. Meyer, A.S. Field, N.L. Kanagy, M. Barton, E.R. Prossnitz

Life Sci 91, 623-627, 2012

Testosterone and secondary hypertension: New pieces to the puzzle
M. Barton, E.R. Prossnitz, M.R. Meyer

Hypertension 59, 1011-1103, 2012

Position paper: The membrane estrogen receptor GPER - clues and questions
M. Barton

Steroids 77, 925-242, 2012

Endothelin and the podocyte
M. Barton, P.L. Tharaux

Clin Kidney J 5, 17-27, 2012

Endothelin receptor antagonists in cardiovascular medicine: Challenges and opportunities
M. Barton
In: Translational Vascular Medicine (D. Abraham, Ed) Springer London, 231-259, 2012

Deletion of the G protein-coupled estrogen receptor increases endothelial vasoconstriction
M.R. Meyer, K. Amann, A.S. Field, C. Hu, H.J. Hathyway, N.L. Kanagy, M.K. Walker, M. Barton, E.R. Prossnitz

Hypertension 59, 507-512, 2012

Childhood obesity: a life-long health risk
M. Barton

Acta Pharmacol Sin 33, 189-193, 2012

Obesity and risk of vascular disease: Importance of endothelium-dependent vasoconstriction
M. Barton, O. Baretella, M.R. Meyer
Br J Pharmacol 165, 591-602, 2012

The G protein-coupled estrogen receptor GPER in physiology and disease
E.R. Prossnitz, M. Barton

Nature Rev Endocrinol 7, 715-726, 2011

Endothelin in renal physiology and disease
Contrib Nephrol 172 (M. Barton, D.E. Kohan, Eds), Karger, Basel, 1-266, 2011

The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function
M.R. Meyer, E.R. Prossnitz, M. Barton

Vascul Pharmacol 55, 17-25, 2011

Endothelin antagonists in clinical trials: Lessons learned
M. Barton, D.E. Kohan

Contrib Nephrol 172, 255-260, 2011

Endothelin and podocyte injury in chronic kidney disease
C. Fligny, M. Barton, P.L. Tharaux

Contrib Nephrol 172, 120-138, 2011

Endothelin antagonism and reversal of proteinuric renal disease in humans
M. Barton

Contrib Nephrol 172, 210-222, 2011

Obesity, insulin resistance and diabetes: sex differences and role of estrogens receptors
M.R. Meyer, D.J. Clegg, E.R. Prossnitz, M. Barton
Acta Physiol (Oxf) 203, 259-269, 2011

GPER/GPR30 and regulation of vascular tone and blood pressure
M.R. Meyer, E.R. Prossnitz, M. Barton

Immunol Endocr Metab Agents Med Chem 4, 255-261, 2011

Estrogen-independent activation of estrogen receptors
M. Barton, M.R. Meyer, E.R. Prossnitz
Hypertension 57, 1056-1057, 2011

The discovery of endothelium-dependent contraction: the legacy of Paul M. Vanhoutte
M. Barton

Pharmacol Res 63, 455-462, 2011

Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans
M. Barton
Biochim Biophys Acta 1802, 1203-1213, 2010

Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis
M. Barton
Pflügers Arch Eur J Physiol 460, 825-837, 2010

Übergewicht und kardiovaskuläres Risiko: Neues zu Pathogenese und Therapie
M.R. Meyer, C.A. Meier
Swiss Medical Forum 10, 358-362, 2010

Anti-inflammatory effects of endothelin receptor antagonists and their importance for treating human disease
M. Barton, P.C. Nett, K. Amann, M.M. Teixeira
Front Cardiovasc Drug Discov 1, 236-258, 2010

Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780
M.R. Meyer, O. Baretella, E.R. Prossnitz, M. Barton
Pharmacology 86, 58-64, 2010

Lung cancer and hormone replacement therapy
M. Barton, M.R. Meyer, J.L. Bolton, E.R. Prossnitz
Lancet 375, 117-118, 2010

Postmenopausal hypertension: Mechanisms and therapy
M. Barton, M.R. Meyer
Hypertension 54, 11-18, 2009

ERα, ERβ, and gpER: novel aspects of estrogen receptor signaling in atherosclerosis
M.R. Meyer, M. Barton
Cardiovasc Res 83, 605-610, 2009

Non-genomic regulation of vascular cell function and growth by estrogen
M.R. Meyer, E. Haas, E.R. Prossnitz, M. Barton
Mol Cell Endocrinol 308, 9-16, 2009

Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER
E.R. Prossnitz, M. Barton
Prostaglandins Other Lipid Mediat 89, 89-97, 2009

Regulatory role of G protein coupled estrogen receptor for vascular function and obesity
E. Haas, I. Bhattacharya, E. Brailoiu, M. Damjanovic, G.C. Brailoiu, X. Gao, L. Mueller-Guerre, A. Gut, R. Minotti, M.R. Meyer, K. Amann, E. Ammann, A. Perez-Dominguez, M. Genoni, D.J. Clegg, N.J. Dun, T.C. Resta, E.R. Prossnitz, M. Barton
Circ Res 104, 288-291, 2009

Getting radical about obesity: new links between fat and heart disease
M. Barton, E. Haas, I. Bhattacharya
Arterioscler Thromb Vasc Biol 29, 447-448, 2009

Morbus Addison bei metastasierendem Bronchuskarzinom
M.R. Meyer, A. Ciurea-Löchel, M. Häfner, B. Senn
Swiss Medical Forum 9, 487-488, 2009

Endothelin - Twenty years from discovery to therapy Matthias Barton, Masashi Yanagisawa
Can J Physiol Pharmacol 86, 485-498, 2008
Reversal of proteinuric renal disease and the emerging role of endothelin
M. Barton
Nature Clin Pract Nephrol 4, 490-498, 2008

Need for research on estrogen receptor function: importance for postmenopausal hormone therapy and atherosclerosis
M.R. Meyer, E. Haas, M. Barton
Gend Med 5 (Suppl. A), S19-S33, 2008

Regional heterogeneity of functional changes in conduit arteries after high-fat diet
I. Bhattacharya, A.L. Mundy, C.C. Widmer, M. Kretz, M. Barton
Obesity (Silver Spring) 16, 743-748, 2008

Schwere Verhaltensstörung mit organischer Ursache
M.R. Meyer, B. Rüegger-Frey, N. Nikolic, I. Bopp-Kistler
Praxis (Bern 1994) 97, 1137-1141, 2008

Fat intake and cardiovascular response
M. Damjanovic, M. Barton
Curr Hypertens Rep 10, 25-31 2008

Inflammation and atherosclerosis
M. Barton, R. Minotti, E. Haas
Circ Res 101, 750-751, 2007

Selective activation of G protein-coupled estrogen receptor GPR30 inhibits vasoconstriction and induces vascular smooth muscle cell ERK1/2 phosphorylation
I. Bhattacharya, M. Damjanovic, S. Hirsiger, E. Haas, A. Gut, L. Mueller-Guerre, R. Henggeler, R. Minotti, E.R. Prossnitz, M. Barton
Circulation 116, II74, 2007

Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefits?
M. Barton, M.R. Meyer, E. Haas
Arterioscler Thromb Vasc Biol 27, 1669-1672, 2007

WISDOM trial, postmenopausal hormone replacement and cardiovascular events: Why it is still not wise to use equine estrogens
M. Barton, M.R.Meyer, I. Bhattacharya, E. Haas
Br Med J Rapid Response, e-pub August 28, 2007

Curriculum: Atherosklerotische Gefässerkrankungen und Stickstoffmonoxid (NO): Die wachsende Bedeutung von hoher Lebenserwartung und Übergewicht für die Klinik
M. Husmann, M. Keller, M. Barton
Swiss Medical Forum 50, 1008-1011, 2007

Distinct roles of estrogen receptors α and β mediating acute vasodilatation of epicardial coronary arteries
T. Traupe, C.D. Stettler, H. Li, E. Haas, I. Bhattacharya, R. Minotti, M. Barton
Hypertension 49, 1364-1370, 2007

Differential effects of 17β-estradiol on function and expression of estrogen receptor α, estrogen receptor β, and GPR30 in arteries and veins of patients with atherosclerosis
E. Haas, M.R. Meyer, U. Schurr, I. Bhattacharya, R. Minotti,
H.H. Nguyen, A. Heigl, M. Lachat, M. Genoni, M. Barton
Hypertension 49, 1358-1363, 2007

Effects of obesity on mortality in patients with unstable angina or non ST-elevation myocardial infarction
M. Barton, M. Husmann
Eur Heart J 28, 2950, 2007

Impaired vascular function in normoglycemic mice prone to autoimmune diabetes: Role of nitric oxide
T. Traupe, P.C. Nett, B. Frank, L. Tornillo, R. Hofmann-Lehmann, L.M. Terracciano, M. Barton
Eur J Pharmacol 557,161-167, 2007

Curriculum: Artériopathies athérosclérotique et monoxyde d’azote (NO) : l’importance clinique d’une espérance de vie plus longue et l’obésité
M. Husmann, M. Keller, M. Barton
Forum Médical Suisse 50, 1008-1011, 2007

Vaskuläre Interaktion zwischen Insulin und LDL Cholesterin
E. Haas, R. Minotti, C. Raselli, A. Hoehn, M. Barton
Dtsch Med Wochensch 132, 20, 2007

Endothelin stimulates vascular hydroxyl radical formation: effect of obesity
A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, K. Baumann, M. Barton
Am J Physiol Regul Integr Comp Physiol  293, R2218-R2224, 2007

Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: Implications for diet-induced obesity
A.L. Mundy, E. Haas, I. Bhattacharya, C.C. Widmer, M. Kretz, R. Hofmann-Lehmann, R. Minotti, M. Barton
Cardiovasc Res 73, 368-375, 2007

Therapeutic potential of direct thrombin inhibitors for atherosclerotic vascular disease
M. Husmann, M. Barton
Expert Opin Investig Drugs 16, 563-567, 2007

Oral direct thrombin inhibitors and atherosclerosis
M. Husmann, M. Barton
International Atherosclerosis Society Online Publication Sept 3, 2007

Antioxidant activity and sex differences of acute vascular effects of amiodarone in advanced atherosclerosis
T. Traupe, M. Keller, E. Fojtu, I. Bhattacharya, M. Lang, H.R. Ha, W. Jochum, A.L. Mundy, M. Barton
J Cardiovasc Pharmacol 50, 578-584, 2007

Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling
M.R. Meyer, E. Haas, M. Barton
Hypertension 47, 1019-26, 2006

Transcriptional regulation of vascular bone morphogenetic protein by endothelin receptors in early autoimmune diabetes mellitus
P.C. Nett, J. Ortmann, J. Celeiro, E. Haas, R. Hofmann-Lehmann, L. Tornillo, L.M. Terraciano, M. Barton
Life Sci 78, 2213-2218, 2006

Recent developments on endothelin antagonists as immunomodulatory drugs - from infection to transplantation medicine.
P.C. Nett, M.M. Teixeira, D. Candinas, M. Barton
Recent Pat Cardiovasc Drug Discov 1, 233-244, 2006

Role of endothelin receptors for renal protection and survival in hypertension. Waiting for clinical trials
M. Barton, J.J. Mullins, M.A. Bailey, M. Kretzler
Hypertension 48, 834-837, 2006

Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats
T. Traupe, J. Ortmann, E. Haas, K. Münter, N. Parekh, R. Hofmann-Lehmann, K. Baumann, M. Barton
J Cardiovasc Pharmacol 47, 456-462, 2006

Beneficial cardiovascular effects of endothelin ETA receptor blockade in established long-term heart failure after myocardial infarction
D. Vetter, S.G. Shaw, R.P. Brandes, K. Münter, W. Vetter, M. Barton
Exp Biol Med (Maywood) 231, 857-60, 2006

Upregulation of endothelin converting enzyme-1 in host liver during chronic cardiac allograft rejection
T. Lattmann, J. Ortmann, S. Horber, S.G. Shaw, M. Hein, M. Barton
Exp Biol Med (Maywood) 231, 899-901, 2006

Long-term effects of endovascular angioplasty on orthostatic vasocutaneous autoregulation in patients with peripheral atherosclerosis
M.J. Husmann, M. Barton, V. Jacomella, A. Silvestro, B.R. Amann-Vesti
J Vasc Surg  44, 993-997, 2006

Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes
J. Ortmann, P.C. Nett, J. Celeiro, R. Hofmann-Lehmann, L. Tornillo, L.M. Terraciano, M. Barton
Exp Biol Med (Maywood) 231, 1030-1033, 2006

Early aging and anatomic heterogeneity determine cyclooxygenase-mediated vasoconstriction to angiotensin II in mice
M. Kretz, A.L. Mundy, C.C. Widmer, M. Barton
J Cardiovasc Pharmacol 48, 30-33, 2006 

Rapid endocytosis of copper-zinc superoxide dismutase into human endothelial cells: role for its vascular activity
E.R. Waelti, M. Barton
Pharmacology 78, 198-201, 2006

Upregulation of endothelin receptor B in human endothelial cells by low-density lipoproteins
G. Muller, R.A. Catar, B. Niemann, M. Barton, L. Kneels, M. Wendel, H. Morawietz
Exp Biol Med (Maywood) 231, 766-771, 2006

Marked heterogeneity of endothelin-mediated contractility and contraction dynamics in mouse renal and femoral arteries
C.C. Widmer, A.L. Mundy, M. Kretz, M. Barton
Exp Biol Med (Maywood) 231, 777-781, 2006

Postural effects on interstitial fluid pressure in humans
M.J. Husmann, M. Barton, B.R. Amann-Vesti, U.K. Franzeck
J Vasc Res 43, 321-326, 2006

Ageing as a determinant of renal and vascular disease: role of endothelial factors
M. Barton
Nephrol Dial Transplant 20, 485-490, 2005

Anatomically distinct activation of endothelin-3 and the L-arginine/nitric oxide pathway in the kidney with advanced aging
T. Lattmann, S. Shaw, K. Münter, W. Vetter, M. Barton
Biochem Biophys Res Commun 327, 234-241, 2005

Ageing as a determinant of renal and vascular disease: role of endothelial factors
M. Barton
Nephrol Dial Transplant 20, 485-490, 2005

Aging and biomedicine 2005: Where should we go from here?
M. Barton
Cardiovasc Res 66, 187-189, 2005

Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen
R.K. Dubey, B. Imthurn, M. Barton, E.K. Jackson
Cardiovasc Res 66 , 295- 306, 2005

Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: evidence for endothelin release by pancreatic islet β-cells.
J. Ortmann, P.C. Nett, J. Celeiro, T. Traupe, L. Tornillo, R. Hofmann-Lehmann, E. Haas, B. Frank, L.M. Terraciano, M. Barton
Biochem Biophys Res Commun 334, 689-695, 2005

Native and oxidized low-density lipoproteins stimulate endothelin-converting enzyme-1 expression in human endothelial cells
B. Niemann, S. Rohrbach, R.A. Catar, G. Muller, M. Barton, H. Morawietz
Biochem Biophys Res Commun 334, 747-753, 2005

Spotlight issue on cardiovascular aging
S. Pepe, E. Lakatta, M. Barton (Eds).
Cardiovasc Res 66 , 1-419, 2005

Endothelin in the microvasculature
M. Barton
In:
Microvascular Research: Biology and Pathobiology (D. Shepro, Ed.), Academic Press, San Diego, pp 5-12, 2005

Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: role of endothelin receptor signaling
T. Lattmann, M. Hein, S. Horber, J. Ortmann, M.M. Teixeira, D.G. Souza, E. Haas, L. Tornillo, K. Münter, W. Vetter, M. Barton
Am J Transplant 5, 1042-1049, 2005

Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition
J. Ortmann, K. Amann, R.P. Brandes, M. Kretzler, K. Münter, N. Parekh, T. Traupe, M. Lange, T. Lattmann, M. Barton
Hypertension 44, 974-981, 2004

Protective Role of ETA endothelin receptors during the acute phase of Trypanosoma cruzi infection in rats
E.R.S. Camargos, L.L.V. Rocha, M.A. Rachid, A.P. Almeida, A.J. Ferreira, A.L. Teixeira-Jr, E. Chiari,
M. Barton, M.M. Teixeira, C.R.S. Machado
Microbes Infect 6, 650-656, 2004

Amiodarone acutely inhibits vascular activity of endothelin-converting enzymes
T. Traupe, M. Lang, J. Ortmann, M. Keller, E. Fojtu, W. Vetter, M. Barton
J Cardiovasc Pharmacol 44, S113-S116, 2004

Upregulation of vascular ETB receptor gene expression after chronic ETA receptor blockade in prediabetic NOD mice
J. Ortmann, T. Traupe, P. Nett, J. Celeiro, R. Hofmann-Lehmann, M. Lange, W. Vetter, M. Barton
J Cardiovasc Pharmacol 44, S105-S108, 2004

In-vivo interactions of nitric oxide and endothelin
T. Lattmann, W. Vetter, M. Barton
J Hypertens 22, 1839-1840, 2004

Protease-activated receptors and EDHF: the icing on the cake?
T. Traupe and M. Barton
Cardiovasc Res 61, 645-647, 2004

Einfluss Postmenopausaler Hormonsubstitution mit konjugierten equinen Oestrogenen und Medroxyprogesteronazetat auf das kardiovaskuläre Risiko
J. Ortmann, W. Vetter, T. Traupe, M. Barton
Schweiz Rundsch Med Prax 93, 904-914, 2004

Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth
L. Emmanuele, J. Ortmann, T. Doerflinger, T. Traupe, M. Barton
Biochem Biophys Res Commun 302, 67-72, 2003

Obesity-associated activation of angiotensin and endothelin in the cardiovascular system
M. Barton, R. Carmona, J. Ortmann, J.E. Krieger, T. Traupe
Int J Biochem Cell Biol 35, 826-837, 2003

Cardiovascular consequences of the obesity pandemic: need for action
M. Barton, J. Furrer
Exp Opin Invest Drugs 12, 1757-1759, 2003
Endothelin, hypercholesterolemia and atherosclerosis
M. Barton, T. Traupe, C.C. Haudenschild
Coron Artery Dis 14, 477-490, 2003

Endothelial therapy of atherosclerosis and its risk factors
T. Traupe, J. Ortmann, K. Münter, M. Barton
Current Vasc Pharmacol 1, 111-121, 2003

Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression
T. Traupe, M. Lang, W. Goettsch, K. Münter, H. Morawietz, W. Vetter, M. Barton
J Hypertens 20, 2239-2245, 2002

Acute effects of 17β-oestradiol on functional activity of endothelin-converting enzymes in human arteries and veins
A. Heigl, M. Lachat, T. Lattmann, T. Luscher, M. Barton
Clin Sci (Lond) 103(S), 438S-441S, 2002

Estrogen and apoptosis in atherosclerosis
M. Barton, M.M. Kockx
Midlife Health - Current Concepts and Challenges for the Future, Samioe G, Skouby S, (Eds.). Proceedings of the
5th European Congress on Menopause, Copenhagen, Denmark, July 1-5, 2000
Elsevier International Congress Series, 81-93, 2002

Postmenopausal hormone-replacement therapy
M. Barton, R.K. Dubey
N Engl J Med 346, 63-65, 2002

Effects of obesity on endothelium-dependent reactivity during acute nitric oxide inhibition: modulatory role of endothelin
T. Traupe, L.V. d'Uscio, K. Muenter, H. Morawietz, W. Vetter, M. Barton
Clin Sci (Lond) 103 (Suppl. 48), 13S-15S, 2002

Role of endothelin during experimental Trypanosoma cruzi infection in rats
E.R.S. Camargos, C.R.S. Machado, A.L. Teixeira-Jr, L.L.V. Rocha, A.J. Ferreira, A.P. Almeida, M. Barton, M.M.Teixeira
Clin Sci (Lond) 103(Suppl. 48), 64S-67S, 2002

Increased expression of endothelin-converting enzyme-1 in failing human myocardium
H. Morawietz, W. Goettsch, M. Szibor, M. Barton, S. Shaw, K. Hakim, H.-R. Zerkowski, J. Holtz
Clin Sci (Lond) 103(Suppl. 48), 237S-240S, 2002

Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Luscher
Cardiovasc Res 53, 487-495, 2002

Native LDL induces proliferation of human vascular smooth muscle cells via a redox-mediated activation of ERK1/2 mitogen-activated protein kinases
R. Locher, R.P. Brandes, W. Vetter, M. Barton
Hypertension 39 (Part 2), 645-50, 2002

Green tea polyphenols inhibit human vascular smooth muscle cell proliferation stimulated by native low-density lipoprotein
R. Locher, L. Emmanuele, P.M. Suter, W. Vetter, M. Barton
Eur J Pharmacol 434, 1-7, 2002

Oral contraceptives and the risk of thrombosis and atherosclerosis
M. Barton, R.K. Dubey, T. Traupe
Exp Opin Invest Drugs 11, 329-332, 2002

Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Luscher
Cardiovasc Res 53, 487-495, 2002

Angiotensin-converting enzyme inhibitor therapy prevents upregulation of endothelin-converting enzyme-1 in failing human myocardium
H. Morawietz, W. Goettsch, M. Szibor, M. Barton, S. Shaw, K. Hakim, H.-R. Zerkowski, J. Holtz
Biochem Biophys Res Commun 295, 1057-61, 2002

Acute effects of 17β-oestradiol on functional activity of endothelin-converting enzymes in human arteries and veins
A. Heigl, M. Lachat, T. Lattmann, T. Luscher, M. Barton
Clin Sci (Lond) 103(S), 438S-441S, 2002

Postmenopausal estrogen replacement therapy and atherosclerosis: Can current compounds provide cardiovascular protection?
M. Barton
Exp Opin Invest Drugs 20, 789-809, 2001

Endothelin receptor blockade and nitric oxide bioactivity
M. Barton, B. Glodny
Cardiovasc Res 52, 161-163, 2001

The therapeutic potential of endothelin receptor antagonists in cardiovascular disease
M. Barton, W. Kiowski
Curr Hypertens Rep 3, 322-330, 2001

Endothelin and cardiac arrhythmias: do endothelin antagonists have therapeutic potential as antiarrhythmic drugs?
F. Duru, M. Barton, T.F. Luscher, R. Candinas
Cardiovasc Res 49, 272-280, 2001

Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo. Implications for atherosclerosis
W. Goettsch, T. Lattmann, K. Amann, M. Szibor, H. Morawietz, K. Münter, S.P. Müller, S. Shaw, M. Barton
Biochem Biophys Res Commun 280, 908-13, 2001

Endothelium and atherogenesis: endothelial therapy revisited
M. Barton, C.C. Haudenschild
J Cardiovasc Pharmacol 38 (Suppl. 2), S23-S25, 2001

Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo. Implications for atherosclerosis
W. Goettsch, T. Lattmann, K. Amann, M. Szibor, H. Morawietz, K. Münter, S.P. Müller, S. Shaw, M. Barton
Biochem Biophys Res Commun 280, 908-13, 2001

M. Barton, R. Carmona, H. Morawietz, L.V. d'Uscio, W. Goettsch, H. Hillen, C.C. Haudenschild,
J.E. Krieger, K. Münter, T. Lattmann, T.F. Luscher, S. Shaw
Hypertension 35, 329-336, 2000

Endothelin and endothelin antagonists. Therapeutic considerations for a novel class of cardiovascular drugs
T.F. Luscher, M. Barton
Circulation 102, 2434-2440, 2000

Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms
of renal artery dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis

M. Barton, I. Vos, S. Shaw, P. Boer, L.V. d'Uscio, H.-J. Gröne, T.J. Rabelink, T. Lattmann, P. Moreau, T.F. Luscher
J Am Soc Nephrol 11, 835-846, 2000

Oestrogensubstitutionstherapie und Arteriosklerose - Pathophysiologie und therapeutische Implikationen
M. Barton
J Menopause 7, 12-15, 2000

Hypertension, diabetes mellitus, hypercholesterolemia and endothelin B receptor-mediated renal nitric oxide release
M. Barton, L.V. d'Uscio
Circulation 101; e228-e229, 2000

Sex and NO - beyond regulation of vasomotor tone
M. Barton
Cardiovasc Res 46, 20-23, 2000

Assessment of coronary flow reserve by contrast-enhanced second harmonic echo Doppler
R. Jenni, A. Linka, M. Barton
Circulation 101, e100, 2000

Deloading of the left ventricle by ventricular assist device normalizes increased expression of endothelin ETA receptors but not endothelin-converting enzyme-1 in patients with end-stage heart failure
H. Morawietz, M. Szibor, W. Goettsch, B. Bartling, M. Barton, S. Shaw, R. Koerfer, H.-R. Zerkowski, J. Holtz
Circulation 102, III188 -III193, 2000

Doppler mirror image artifacts mimicking mitral regurgitation in patients with mechanical bileaflet mitral valve prostheses
A.Z. Linka, M. Barton, C. Attenhofer Jost, R. Jenni
Eur Heart J Cardiovasc Imag 1, 138-43, 2000

Ventricular arrhythmias induced by endothelin-1 or by acute ischemia: a comparative analysis using three dimensional mapping
F. Duru, M. Barton, R. Candinas
Cardiovasc Res 46, 604-605, 2000

Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade
M. Burkhardt, M. Barton, S.G. Shaw
J Hypertens 18, 273-279, 2000

Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics
M. Barton
Curr Hypertens Reports 2, 84-91, 2000

Endothelin und Atherosklerose. Kausale Bedeutung und therapeutische Implikationen
M. Barton
Kardiovask Med 3, 13-18, 2000

Endothelin in atherosclerosis: importance of risk factors and therapeutic implications
L.V. d'Uscio, M. Barton, S. Shaw, T.F. Luscher
J Cardiovasc Pharmacol 35 (4 suppl 2), S55-S59, 2000

Inverse regulation of endothelin-1 and nitric oxide metabolites in tissue with aging: implications for the age-dependent increase of cardiorenal disease
M. Barton, T. Lattmann, L.V. d'Uscio, T.F. Luscher, S. Shaw
J Cardiovasc Pharmacol 36 (Suppl.1), S153-S156, 2000

Endothelin regulates angiotensin-converting enzyme in the mouse kidney
M. Barton, R. Carmona, J.E. Krieger, W. Göettsch, H. Morawietz, L.V. d'Uscio, T. Lattmann, T.F. Luscher, S. Shaw
J Cardiovasc Pharmacol 36 (Suppl.1), S244-S247, 2000

Endothelin antagonists for hypertension and renal disease
M. Barton, T.F. Luscher
Curr Opin Nephrol Hypertens 8, 549-556, 1999

Endothelial dysfunction in acute renal faiulre: role of circulating and tissue endothelin-1
F. Ruschitzka, S. Shaw, D. Gygi, G. Noll, M. Barton, T.F. Luscher
J Am Soc Nephrol 10, 953-962, 1999

Endothelial dysfunction in the aorta of transgenic rats harboring the mouse ren-2 gene
U.A. Arnet, D. Novosel, M. Barton, G. Noll, D. Ganten, T.F. Luscher
Endothelium 6, 175-184, 1999

Estrogen and vascular resistance
M. Barton, T.F. Luscher
Curr Opin Endocrinol Diabet 6, 218-224, 1999

Vascular effects of estrogens: rapid actions, novel mechanisms, and potential therapeutic implications
M. Barton
Acta Pharmacol Sin 20, 682-690, 1999

Endothelin in heart failure
G. Sutsch, M. Barton
Curr Hypertens Reports 1, 62-68, 1999

Vascular effects of estrogen
E. Wight, M. Barton, E. Espinosa, T. Luscher.
In: Menopause and the Heart (T.B. Clarkson, P. Collins, Eds), Taylor & Francis, Philadelphia; 1, pp 1-7, 1999

Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
M. Barton, C.C. Haudenschild, L.V. d`Uscio, S. Shaw, K. Münter, T.F. Luscher
Proc Natl Acad Sci U.S.A. 95, 14367-14372, 1998

ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension
M. Barton, L.V. d`Uscio, S. Shaw, P. Meyer, P. Moreau, and T.F. Luscher
Hypertension 31, 499-504, 1998

Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase. Role of blood pressure and endothelial function
L.V. d`Uscio, S. Shaw, M. Barton, T.F. Luscher
Hypertension 31, 1305-1310, 1998

Endothelial aging. A determinant of cardiovascular risk
M. Barton
In: Cardiovascular Aging. Physiology, Physiology, Pharmacology and Therapeutics. IUPHAR Satellite Symposium, Nancy, France, July 23-24, 1998
Cardiovasc Drug Rev 3, 300-311, 1998

Salt Wars
M. Barton, T.F. Luscher, T.J. Rabelink
Science 281, 1961, 1998

Endothelial vasoconstrictor prostanoids, vascular reactivity, and acute renal failure
F. Ruschitzka, S. Shaw, G. Noll, M. Barton, E. Schulz, G.A. Müller, T.F. Luscher
Kidney Int 67, S199-S201, 1998

Differential modulation of the renal myocardial endothelin system by angiotensin II in vivo: effects of chronic selective ETA receptor blockade
M. Barton, S. Shaw, L. V. d'Uscio, P. Moreau, T.F. Luscher
J Cardiovasc Pharmacol 31 (Suppl 1), S265-S268, 1998

17β-Estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries
M. Barton, J. Cremer, A. Mügge
Eur J Pharmacol 362, 73-76, 1998

Endothelium-independent relaxation and hyperpolarization to C-type natriuretic peptide in porcine coronary arteries
M. Barton, J.L. Bény, L.V. d`Uscio, T. Wyss, G. Noll, T.F. Luscher
J Cardiovasc Pharmacol 31, 377-383, 1998

Biology of the endothelium
T.F. Luscher, M. Barton
Clin Cardiol 20 (Suppl. II), 3-10, 1997

Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: Role of ETA receptors for endothelin regulation
M. Barton, S. Shaw, L.V. d`Uscio, P. Moreau, T.F. Luscher
Biochem Biophys Res Commun 238, 861-865, 1997

Structure and function of small arteries in salt-induced hypertension: effects of chronic endothelin-subtype-A-receptor blockade
L.V. d'Uscio, M. Barton, S. Shaw, P. Moreau, T.F. Luscher
Hypertension 30, 905-911, 1997

Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ETA-receptor antagonist
P. Moreau, L. V. d'Uscio, S. Shaw, H. Takase, M. Barton, T.F. Luscher
Circulation 96, 1593-1597, 1997

Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension
L.V. d`Uscio, P. Moreau, S. Shaw, H. Takase, M. Barton, T.F. Luscher
Hypertension 29, 435-441, 1997
                                    
Endothelial-derived superoxide anions in pig coronary arteries: evidence from lucigenin chemiluminescence and histochemical techniques
R.P. Brandes, M. Barton, K.M.H. Philippens, G. Schweitzer, A. Mügge
J Physiol (Lond) 500, 331-342, 1997

The endothelium as therapeutic target for atherosclerosis. Importance of ACE inhibition and cholesterol lowering
M. Barton, T.F. Luscher
Thoraxcenter J 9, 12-19, 1997

Anatomic heterogeneity of vascular aging. Role of nitric oxide and endothelin
M. Barton, F. Cosentino, R.P. Brandes, P. Moreau, S. Shaw, T.F. Luscher
Hypertension 30, 817-824, 1997

Contractile responses to histamine, serotonin, and angiotensin II are impaired by 17β-estradiol in human internal mammary arteries in vitro
A. Mügge, M. Barton, H.G. Fieguth, M. Riedel
Pharmacology 54, 162-168, 1997

Gefässprotektion durch Oestrogene. Wirkungen in vitro und in vivo - Mechanismen und klinische Implikationen
M. Barton, E. Wright, D.D. Do, Z. Yang, E. Espinosa, U. Arnet, T.F. Luscher
Schweiz Rundsch Med (PRAXIS) 86, 129-137, 1997

17β-Oestradiol inhibits growth of human vascular smooth muscle: similar effects in cells from females and males
Z. Yang, D.D. Do, E. Espinosa, M. Barton, A. Arnet, T. F. Luscher
J Cardiovasc Pharmacol 28 (Suppl. 5), S34-S39, 1996

Wirkungen natürlicher Oestrogene auf die Gefässwand: Molekulare Mechanismen und klinische Implikationen
T.F. Luscher, M. Barton, E. Wight, E. Espinosa, Z. Yang
Schweiz Med Wschr 126, 1748-1755, 1996

Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery
M.R. Tschudi, M. Barton, N.A. Bersinger, P. Moreau, F. Cosentino, G. Noll, T. Malinski, T.F. Luscher
J Clin Invest 98, 899-905, 1996

Different vascular reactivity of human internal mammary and inferior epigastric arteries in vitro
A. Mügge, M. Barton, J. Cremer, R. Frombach, P.R. Lichtlen
Ann Thorac Surg 56, 1085-1089, 1993

Endothelium-independent relaxation by 17β-oestradiol of human coronary arteries in vitro
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R. Lichtlen
Cardiovasc Res 27, 1939-1942, 1993

Estrogen dilates human coronary arteries in vitro by an increase in cyclic GMP and cyclic AMP smooth muscle content
A. Mügge, M. Riedel, M. Barton, M. Kuhn, P.R. Lichtlen
Eur Heart J 14, 16, 1993

17β-Oestradiol dilates both human internal and coronary arteries by an endothelium-independent mechanism.
M. Barton, M. Riedel, A. Mügge
Naunyn-Schmiedeberg's Arch Pharmacol 347, 43, 1993

Comparison of endothelium-dependent and endothelium-independent relaxations in human internal thoracic and inferior epigastric arteries in vitro
A. Mügge, J. Cremer, M.R. Schulze, M. Barton, P.R. Lichtlen
Circulation 86, 832, 1992